Ophiomics

Ophiomics is an ISO 13485 and ISO 9001 certified, clinical-stage Medtech company developing cutting-edge diagnostic products and services integrating bioinformatics, artificial intelligence and genomics in support of diagnostic, prognostic, treatment selection and clinical follow-up in oncology. Our vision: To lead the world in cancer diagnostics and transform the future of healthcare. Our Mission: We are committed to revolutionizing cancer diagnostics worldwide by leveraging the power of AI and genomics to develop a cutting-edge portfolio of technology-driven, cost-effective products with a massive global impact, significantly enhancing health outcomes. Ophiomics was founded in 2015 by José Pereira Leal and Joana Cardoso Vaz. The name “Ophiomics” reflects our origins and the cutting-edge technology we develop to advance the medical field. Ophiomics is now participating in the IPOready program by Euronext. Our end-products – IVD medical devices – are designed to seamlessly integrate into routine clinical practice, ensuring accessibility and ease of adoption. Joana Cardoso Vaz, PhD, is a cancer genomics specialist, with extensive experience in collaborating with clinicians, spanning the journey from biomarker discovery to clinical diagnosis.